NASDAQ$AXGN

Axogen Inc. · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Axogen's financial results decreased compared to the second quarter of 2019.

Axogen reported a decrease in net revenue by 17% compared to Q2 2019, with a net loss of $8.1 million. The company secured a new financing agreement for up to $75 million and saw an increase in cash, cash equivalents, and investments to $109.9 million.

  • Net revenue was $22.1 million, a 17% decrease compared to Q2 2019.
  • Gross margin was 74.7%, compared to 84.1% in Q2 2019.
  • Net loss was $8.1 million, or $0.20 per share, compared to a net loss of $7.0 million, or $0.18 per share, in Q2 2019.
  • Cash, cash equivalents, and investments totaled $109.9 million as of June 30, 2020.

Headline financials

Total Revenue

$22.1M

Previous: $26.7M-17.2%
EPS (adj)

-$0.15

Previous: -$0.10-50.0%
Capital Expenditures

-$13.2M

Previous: -$1.69M-682.4%
Free Cash Flow

-$21.3M

Previous: -$8.71M-144.5%
Net Income

-$8.11M

Previous: -$7.02M-15.4%
Operating Income

-$8.25M

Previous: -$7.67M-7.6%
Gross Profit

$16.5M

Previous: $22.5M-26.5%
Cash & Equivalents

$75.3M

Previous: $24.9M+202.8%
Total Assets

$170M

Previous: $157M+8.5%
Stock-Based Comp

$2.22M

No prior period

Revenue & EPS history

Axogen · Revenue · Quarterly

$22.1M

Q2 2020-17.2%vs Q2 2019
Beat estimate in 5 of 16 quarters(31%)
ActualEstimate

Forward guidance

Axogen anticipates that most deferred procedures will be scheduled by the end of the summer. The company expects revenue in the third and fourth quarters will continue to trend below prior-year results.

Tailwinds

  • Commercial team performed well.
  • Demand for products increased as surgery schedules opened.
  • Hospitals quickly moved to complete nerve repair procedures.
  • Most deferred nerve repair procedures will be scheduled by the end of the summer.
  • Balance sheet strength and cost mitigation initiatives will allow the company to emerge stronger.

Headwinds

  • Regional COVID-19 resurgence may continue to negatively impact trauma incidence.
  • Regional COVID-19 resurgence may continue to negatively impact surgical procedure volumes in certain geographies.
  • Revenue in the third and fourth quarters is expected to continue to trend below prior-year results.
  • Suspended the 2020 annual financial guidance.
  • Cannot predict the extent or duration of the impact of the COVID-19 pandemic on its financial results

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+1.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+6.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+39.1%

Q2 2024

Best reaction

-27.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+9.9%+2.6%
Q4 2025-6.6%-10.3%-8.8%
Q3 2025+22.8%+28.6%+58.5%
Q1 2025-23.2%-33.6%-33.4%
Q4 2024+11.7%+11.1%+5.4%
Q3 2024-17.4%-13.4%-2.7%
Q2 2024+39.1%+42.2%+64.4%
Q1 2024-11.7%-11.1%+4.1%
Q4 2023-14.4%-17.4%-26.7%
Q3 2023+37.4%+27.7%+88.8%
Q2 2023-20.8%-27.9%-27.0%
Q1 2023-1.8%-4.6%-0.8%
Q4 2022+11.6%+9.2%+37.8%
Q3 2022+19.0%+21.4%+0.6%
Q2 2022+2.1%+1.2%-10.7%
Q1 2022+23.4%+17.7%+16.8%
Q4 2021+8.0%+27.1%+6.2%
Q3 2021-13.3%-6.0%-37.3%
Q2 2021-2.5%-9.5%-12.5%
Q1 2021+14.9%+13.3%-1.2%
Q4 2020+3.6%+7.0%-7.7%
Q3 2020+3.4%+10.4%+18.0%
Q2 2020+0.3%-2.3%-1.7%
Q1 2020-14.7%-9.6%+10.9%
Q4 2019-17.6%-15.8%-36.3%
Q3 2019+12.4%+13.3%+23.8%
Q2 2019-27.3%-21.8%-5.5%
Q1 2019-2.1%-5.4%-15.7%
Q4 2018+1.6%+6.7%+13.4%
Q3 2018+9.3%+12.8%-1.3%
Q2 2018-12.6%-13.1%-2.4%
Q1 2018-5.1%+5.2%+14.2%
Q4 2017+8.8%+4.5%+17.0%
Q3 2017+10.7%+15.3%+28.5%
Q2 2017-4.8%-6.4%+14.7%
Q1 2017+3.3%+3.7%+25.6%
Q4 2016-0.5%-0.5%-5.2%
Q3 2016-1.7%-10.9%-7.4%
Q2 2016+25.1%+26.2%+32.9%
Q1 2016-0.4%
Q4 2015-4.7%
Q3 2015+17.3%
Q2 2015+5.4%
Q1 2015+3.1%
Q4 2014+3.8%
Q3 2014+5.5%
Q2 2014+1.3%
Q1 2014+1.6%
Q4 2013-8.5%
Q3 2013+1.8%
Q2 2013-0.3%
Q1 2013-14.7%
Q4 2012+4.5%
Q3 2012-1.8%
Q2 2012+18.2%
Q1 2012+0.3%
Q4 2011-4.5%
Q3 2011-14.8%
Q2 2010+0.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010-6.8%
Q3 2010+9.7%
Q1 2010-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro